Neuropsychopharmacology Division, Department of Pharmacy, Birla Institute of Technology and Science, Pilani, India.
Neuropsychopharmacology Division, Department of Pharmacy, Birla Institute of Technology and Science, Pilani, India; R&D Healthcare Division, Emami Ltd, Kolkatta, India.
Neurosci Lett. 2021 Apr 17;750:135769. doi: 10.1016/j.neulet.2021.135769. Epub 2021 Feb 23.
Continual strategies to devise a complete therapeutic cure for neurodegenerative conditions has been a challenge, majorly due to the presence of blood brain barrier. Lack of targeted delivery in order to minimize loss of dopamine (DA) neurones has been a major challenge to overcome anomalies in Parkinson Disease (PD). PD is a neuromotor degenerative disorder deteriorating motor coordination in affected individuals. Recent research has highlighted the use of lentiviral vectors (LVs) for selective delivery of neuroprotective substance for complete halt of disease progression in PD. LVs have the ability to infect both dividing and non-dividing cells along with non-encoding capability of viral protein that might elicit an immune response. This review will mainly focus on understanding the basic mechanism of action of LVs and its therapeutic aid in PD.
为神经退行性疾病设计完整治疗方法的持续策略一直是一个挑战,主要是由于血脑屏障的存在。为了最大限度地减少多巴胺 (DA) 神经元的损失,实现靶向递送一直是克服帕金森病 (PD) 异常的主要挑战。PD 是一种神经运动退行性疾病,会降低受影响个体的运动协调性。最近的研究强调了使用慢病毒载体 (LV) 来选择性递送达保护物质,以完全阻止 PD 中的疾病进展。LV 能够感染分裂和非分裂细胞,并且具有非编码病毒蛋白的能力,这可能会引发免疫反应。本综述将主要侧重于了解 LVs 的基本作用机制及其在 PD 中的治疗辅助作用。